Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Without treatment, their blood sugar can spike - dangerously. Glucose monitors, healthy dietary choices, scheduled exercise, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

The Tamil Nadu government is actively supporting children diagnosed with Type 1 diabetes by providing free insulin injections ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...